Categories: News

AGTC to Host First Quarter Financial Results Conference Call and Webcast on November 9, 2021

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases, today announced that it will report financial results for the quarter ended September 30, 2021 before the market opens on Tuesday, November 9, 2021. AGTC management will host a conference call beginning at 8:00 AM Eastern Time on the same day to review the financial results and provide a corporate update.

To access the call, dial 877-407-6184 (US) or 201-389-0877 (outside of the US). A live webcast will be available in the Events and Presentations section of the Investor Relations page at http://ir.agtc.com/events-and-presentations. Please log in approximately 10 minutes prior to the scheduled start time. The archived webcast will be available in the Events and Presentations section of the company’s website.

About AGTC

AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies with the potential to address real patient needs. AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company’s industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders, including entering into strategic partnerships with companies including Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, LLC, an innovator in the emerging field of optogenetics and retinal coding.

IR Contact: 
David Carey
Lazar FINN Partners
T: (212) 867-1768
david.carey@finnpartners.com

Corporate Contact:
Jon Lieber
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5778
jlieber@agtc.com

Staff

Recent Posts

NSCEB Announces Biotech Across America Roadshow, Makes First Stop in North Carolina

NSCEB is launching a 3-month tour of the booming U.S. biotechnology ecosystem  RALEIGH, N.C., June…

1 hour ago

NextGen Healthcare Welcomes Madison Dearborn Partners as New Investment Partner and Announces Planned Leadership Succession

MDP Completes Acquisition of Significant Ownership Position in NextGen Healthcare and Partners with Thoma Bravo…

13 hours ago

Rocketseed launches essential email signature guide for healthcare organizations

New resource helps healthcare providers improve branded communication, ensure HIPAA compliance, and boost patient engagement…

13 hours ago

Hospital PMI® at 52%; May 2025 Hospital ISM® Report On Business®

TEMPE, Ariz., June 6, 2025 /PRNewswire/ -- Economic activity in the hospital subsector expanded in…

13 hours ago

Infisical Secures $16M Series A to Redefine Enterprise Secrets, Identity, and Access Management

Open-source leader democratizes enterprise-grade secrets management for fastest-growing startups, Fortune 500 enterprises, and nation-states. SAN…

13 hours ago

Choctaw Nation and Healthy Together Launch Streamlined Summer EBT Program in Just Six Weeks

MIAMI, June 6, 2025 /PRNewswire/ -- Healthy Together, a leading provider of health and human…

13 hours ago